A Cancer Research UK Phase I trial of the Anti-CD19 DI-B4 monoclonal antibody given intravenously, weekly for four weeks in patients with advanced CD19 positive indolent B-cell malignancies.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs DI B4 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2016 Status changed from recruiting to completed.
- 03 Dec 2015 Accrual to date is 76% according to United Kingdom Clinical Research Network record.